Home > AChE & > Rivastigmine Tartrate

Rivastigmine Tartrate

酒石酸卡巴拉汀,ENA713,ENA-713,ENA 713

Rivastigmine tartrate (酒石酸卡巴拉汀) 是胆碱酯酶抑制剂，IC50为5.5 uM，还能抑制丁酰胆碱酯酶和乙酰胆碱酯酶。

目录号
EY0285
EY0285
EY0285
EY0285
纯度
99.44%
99.44%
99.44%
99.44%
规格
50 mg
100 mg
200 mg
500 mg
原价
570
860
1000
2200
售价
570
860
1000
2200
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Rivastigmine Tartrate is a cholinesterase inhibitor with IC50 of 5.5 μM, and used as a parasympathomimetic or cholinergic agent for the treatment of mild to moderate Alzheimer disease.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] A Servello et. Al. Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type). Minerva medica, 105(2), 167-174 (2014).
    [2] Steven H Ferris and Martin Farlow. Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clinical Interventions in Aging, 8, 1007-1014 (2013)

    分子式
    C18H28N2O8    		 分子量
    400.42    		 CAS号
    129101-54-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    42 mg/mL    		 Water
    80 mg/mL    		 Ethanol
    80 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00624663 Rivastigmine Toxicity Drug: Rivastigmine Tel-Aviv Sourasky Medical Center|Medical Corps, Israel Defense Force 2009-01-01 2014-03-26
    NCT02063269 Alzheimer's Disease Drug: Rivastigmine Seoul National University Hospital|Novartis Korea Ltd. 2014-02-01 2015-05-12
    NCT01073319 Methamphetamine Dependence|Substance Abuse|Methamphetamine Abuse Other: Placebo|Drug: Rivastigmine|Drug: Rivastigmine Baylor College of Medicine|National Institute on Drug Abuse (NIDA) Phase 1 2009-07-01 2012-07-25
    NCT00623103 Parkinson's Disease Dementia Drug: Rivastigmine capsule|Drug: Rivastigmine transdermal patch Novartis Phase 3 2008-01-01 2011-10-19
    NCT01146041 Healthy Drug: Rivastigmine Dr. Reddy's Laboratories Limited Phase 1 2004-02-01 2010-06-16
    NCT01146067 Healthy Drug: Rivastigmine Dr. Reddy's Laboratories Limited Phase 1 2004-01-01 2012-01-12
    NCT01183806 Alzheimer Disease Drug: Rivastigmine|Other: Exercise training program Federal University of Bahia Phase 3 2010-07-01 2012-03-19
    NCT01585272 Alzheimer's Dementia Drug: ENA713 Novartis Pharmaceuticals|Novartis Phase 4 2012-08-01 2016-09-22
    NCT01948791 Alzheimer's Disease Drug: ENA713 Novartis Pharmaceuticals|Novartis Phase 4 2014-08-01 2016-12-20
    NCT02703636 Mild to Moderate Alzheimer's Disease Drug: Rivastigmine Patch Novartis Pharmaceuticals|Novartis Phase 4 2016-05-01 2016-11-18
    NCT00622713 Alzheimer's Disease Drug: Rivastigmine transdermal patch Novartis Phase 4 2008-01-01 2011-06-27
    NCT01084135 Down Syndrome Drug: Rivastigmine|Other: Liquid Placebo Duke University|Taishoff Family Foundation|Hugo W. Moser Research Institute at Kennedy Krieger, Inc. Phase 1|Phase 2 2009-11-01 2015-03-17
    NCT02444637 Alzheimer Disease|CVA (Cerebrovascular Accident) Drug: Rivastigmine National Neuroscience Institute Phase 4 2015-04-01 2015-05-11
    NCT00835159 Delirium|Postoperative Cognitive Dysfunction Drug: Rivastigmine Patch|Other: Placebo Patch New York University School of Medicine|Novartis Phase 4 2008-12-01 2015-01-26
    NCT00748007 Down Syndrome Drug: Rivastigmine National Taiwan University Hospital 2008-01-01 2012-11-27

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：